Paiva, Bruno

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 4,978

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 3,061

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

Mateos, M.-V., Hernández, M.-T., Giraldo, P., de la Rubia, J., de Arriba, F., Corral, L. L., Rosiñol, L., Paiva, B., Palomera, L., Bargay, J., et al. (2013) · New England Journal of Medicine

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 1,171

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

Mateos, M.-V., Oriol, A., Martínez-López, J., Gutiérrez, N., Teruel, A.-I., de Paz, R., García-Laraña, J., Bengoechea, E., Martín, A., Mediavilla, J. D., et al. (2010) · The Lancet Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 458

A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma

Munshi, N. C., Avet-Loiseau, H., Anderson, K. C., Neri, P., Paiva, B., Samur, M., Dimopoulos, M., Kulakova, M., Lam, A., Hashim, M., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 431

Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

Martinez-Lopez, J., Lahuerta, J. J., Pepin, F., González, M., Barrio, S., Ayala, R., Puig, N., Montalban, M. A., Paiva, B., Weng, L., et al. (2014) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 425

Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma

Ledergor, G., Weiner, A., Zada, M., Wang, S.-Y., Cohen, Y. C., Gatt, M. E., Snir, N., Magen, H., Koren-Michowitz, M., Herzog-Tzarfati, K., et al. (2018) · Nature Medicine

Multiple Myeloma Research and TreatmentsSingle-cell and spatial transcriptomics

Cited by 263

Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma

Rosiñol, L., Oriol, A., Rios, R., Sureda, A., Blanchard, M. J., Hernández, M. T., Martínez-Martínez, R., Moraleda, J. M., Jarque, I., Bargay, J., et al. (2019) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 219

PD-L1/PD-1 presence in the tumor microenvironment and activity of PD-1 blockade in multiple myeloma

Paiva, B., Azpilikueta, A., Puig, N., Ocio, E. M., Sharma, R., Oyajobi, B. O., Labiano, S., San-Segundo, L., Rodriguez, A., Aires-Mejia, I., et al. (2015) · Leukemia

Cancer Immunotherapy and BiomarkersMultiple Myeloma Research and Treatments

Cited by 192

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE

San-Miguel, J., Avet-Loiseau, H., Paiva, B., Kumar, S., Dimopoulos, M. A., Facon, T., Mateos, M.-V., Touzeau, C., Jakubowiak, A., Usmani, S. Z., et al. (2022) · Blood

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 153

CAR density influences antitumoral efficacy of BCMA CAR T cells and correlates with clinical outcome

Rodriguez-Marquez, P., Calleja-Cervantes, M. E., Serrano, G., Oliver-Caldes, A., Palacios-Berraquero, M. L., Martin-Mallo, A., Calviño, C., Español-Rego, M., Ceballos, C., Lozano, T., et al. (2022) · Science Advances

CAR-T cell therapy researchT-cell and B-cell Immunology

Cited by 109

Circulating tumor and immune cells for minimally invasive risk stratification of smoldering multiple myeloma

Termini, R., Žihala, D., Terpos, E., Perez-Montaña, A., Jelínek, T., Raab, M., Weinhold, N., Mai, E. K., Grab, A. L., Corre, J., et al. (2022) · Clinical Cancer Research

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 54

Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

Carrasco-Leon, A., Ezponda, T., Meydan, C., Valcárcel, L. V., Ordoñez, R., Kulis, M., Garate, L., Miranda, E., Segura, V., Guruceaga, E., et al. (2021) · Leukemia

Multiple Myeloma Research and TreatmentsCancer-related molecular mechanisms research

Cited by 50

Curative strategy for high-risk smoldering myeloma: carfilzomib, lenalidomide, and dexamethasone (KRd) followed by transplant, KRd consolidation, and Rd maintenance

Mateos, M.-V., Martínez-López, J., Rodriguez Otero, P., González-Calle, V., Gonzalez, M. S., Oriol, A., Gutiérrez, N. C., Ríos-Tamayo, R., Rosiñol, L., Alvarez Rivas, M. A., et al. (2024) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes

Cited by 39

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

Medina-Herrera, A., Vazquez, I., Cuenca, I., Rosa-Rosa, J. M., Ariceta, B., Jimenez, C., Fernandez-Mercado, M., Larrayoz, M. J., Gutierrez, N. C., Fernandez-Guijarro, M., et al. (2024) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 11